These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 9039063)
1. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society. Can J Cardiol; 1997 Jan; 13(1):33-45. PubMed ID: 9039063 [No Abstract] [Full Text] [Related]
2. The Canadian Cardiovascular Society and reference-based drug pricing. Olley PM; McLaughlin PR Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521 [No Abstract] [Full Text] [Related]
3. Coverage of drug costs: reference-based pricing. McGregor M Can J Cardiol; 1998 May; 14(5):666-8. PubMed ID: 9627520 [TBL] [Abstract][Full Text] [Related]
5. Reference-based pricing (RBP) of prescription drugs. Holbrook A; O'Brien B; Grootendorst P Can J Cardiol; 1997 Jul; 13(7):689-90. PubMed ID: 9251582 [No Abstract] [Full Text] [Related]
6. Reference-based pricing in British Columbia: implications for cardiologists--an analysis. Boulet AP; Tessier G Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064 [TBL] [Abstract][Full Text] [Related]
7. Another war on drugs. European countries turn to 'reference pricing' in battle against soaring cost of pharmaceuticals. Hensley S Mod Healthc; 1999 Nov; 29(46):38-9. PubMed ID: 10662043 [No Abstract] [Full Text] [Related]
8. The change of cost: reference-based pricing and the statins. Thomas M Can J Cardiol; 1999 May; 15(5):535-8. PubMed ID: 10350662 [No Abstract] [Full Text] [Related]
9. HSFC/CCS statement on the use of sildenafil. Heart and Stroke Foundation of Canada/Canadian Cardiovascular Society. Smith ER Can J Cardiol; 1999 Apr; 15(4):475. PubMed ID: 10322258 [No Abstract] [Full Text] [Related]
10. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. Augurzky B; Göhlmann S; Gress S; Wasem J Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725 [TBL] [Abstract][Full Text] [Related]
11. Drug treatment and cost of cardiovascular disease in Australia. Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C; Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615 [TBL] [Abstract][Full Text] [Related]
12. Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes. Swinburn B; Milne RJ; Richards M; Begg E; Foote S; Jackson R N Z Med J; 2000 Oct; 113(1119):425-8. PubMed ID: 11127362 [No Abstract] [Full Text] [Related]
13. Opinion: price controls on prescription drugs. Franks B N J Med; 2004 Apr; 101(4):56, 55. PubMed ID: 15103791 [No Abstract] [Full Text] [Related]
14. [Cardiologies reflect on cost cuts. Waste with heart drugs?]. Schumacher B MMW Fortschr Med; 2003 Sep; 145(38):4-5. PubMed ID: 14603669 [No Abstract] [Full Text] [Related]
15. Prescription drug prices in Canada. Gross D Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123 [No Abstract] [Full Text] [Related]
16. Canadian Task Force for Cardiovascular Science. A Joint Initiative of the Heart and Stroke Foundation of Canada and the Canadian Cardiovascular Society. Can J Cardiol; 1993 Oct; 9(8):699-735. PubMed ID: 8269356 [No Abstract] [Full Text] [Related]